Jefferies Financial Group Inc. Has $12.54 Million Position in Alphatec Holdings, Inc. $ATEC

Jefferies Financial Group Inc. raised its stake in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 983.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 595,937 shares of the medical technology company’s stock after purchasing an additional 540,937 shares during the period. Jefferies Financial Group Inc.’s holdings in Alphatec were worth $12,539,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Alphatec by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 6,883,626 shares of the medical technology company’s stock valued at $144,831,000 after acquiring an additional 68,568 shares during the period. American Century Companies Inc. boosted its position in shares of Alphatec by 2.6% in the third quarter. American Century Companies Inc. now owns 6,336,491 shares of the medical technology company’s stock valued at $92,133,000 after acquiring an additional 159,330 shares during the period. Two Sigma Investments LP boosted its position in shares of Alphatec by 59.0% in the third quarter. Two Sigma Investments LP now owns 1,794,324 shares of the medical technology company’s stock valued at $26,089,000 after acquiring an additional 665,634 shares during the period. Aberdeen Group plc boosted its position in shares of Alphatec by 29.7% in the fourth quarter. Aberdeen Group plc now owns 1,286,195 shares of the medical technology company’s stock valued at $27,062,000 after acquiring an additional 294,792 shares during the period. Finally, Assenagon Asset Management S.A. boosted its position in shares of Alphatec by 30.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 978,343 shares of the medical technology company’s stock valued at $20,584,000 after acquiring an additional 227,914 shares during the period. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ATEC. Lake Street Capital reissued a “buy” rating and issued a $15.00 target price on shares of Alphatec in a research report on Wednesday, May 6th. Piper Sandler reissued an “overweight” rating and issued a $14.00 target price (down from $25.00) on shares of Alphatec in a research report on Wednesday, May 6th. Needham & Company LLC reduced their target price on shares of Alphatec from $25.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Wall Street Zen raised shares of Alphatec from a “hold” rating to a “buy” rating in a research report on Saturday, January 31st. Finally, Barclays reduced their target price on shares of Alphatec from $27.00 to $24.00 and set an “overweight” rating for the company in a research report on Thursday, May 7th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Alphatec currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.58.

Alphatec Stock Performance

ATEC opened at $8.27 on Monday. Alphatec Holdings, Inc. has a twelve month low of $6.82 and a twelve month high of $23.29. The company has a 50-day simple moving average of $10.32 and a 200 day simple moving average of $15.17. The company has a quick ratio of 1.12, a current ratio of 1.90 and a debt-to-equity ratio of 40.35. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -10.09 and a beta of 0.96.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings data on Tuesday, May 5th. The medical technology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.21). Alphatec had a negative return on equity of 1,183.84% and a negative net margin of 15.93%.The firm had revenue of $192.11 million for the quarter, compared to the consensus estimate of $197.51 million. During the same period in the prior year, the company earned ($0.35) EPS. The company’s revenue for the quarter was up 13.6% compared to the same quarter last year. Analysts predict that Alphatec Holdings, Inc. will post -0.44 EPS for the current fiscal year.

Insider Activity

In related news, EVP Craig E. Hunsaker sold 82,765 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $12.45, for a total transaction of $1,030,424.25. Following the completion of the sale, the executive vice president owned 1,726,209 shares of the company’s stock, valued at $21,491,302.05. This represents a 4.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Scott Lish sold 260,535 shares of the company’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $12.30, for a total transaction of $3,204,580.50. Following the sale, the chief operating officer directly owned 815,704 shares of the company’s stock, valued at $10,033,159.20. This represents a 24.21% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 629,189 shares of company stock worth $7,801,589. 13.48% of the stock is owned by company insiders.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.